
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Nasdaq Global Market: $XENENeuroscience and ion channel therapeutics
XENE Stock Hub: Xenon Pharmaceuticals News, Azetukalner and Epilepsy
Xenon reported third-quarter 2026 results after the U.S. close on November 9, 2026: a net loss of $110.4 million, or $1.11 per share, on research and development expense of $95.6 million, with $1.1535 billion of cash, equivalents and marketable securities at September 30 and funding guided into 2029. The azetukalner application for focal seizures, submitted in September, awaits FDA filing review. New enrollment in psychiatry studies stays paused, but X-NOVA2 enrollment is complete at about 360 patients and topline results are now guided to December 2026. The shares closed at $40.45 on November 9, before the release, and at $41.39 on November 10.
Full research report · PDF
Xenon Pharmaceuticals research · November 10, 2026
23 pages covering the business, the third-quarter 2026 accounts, financial resources, catalysts, the November 10 close and the conference schedule, risks and sources. A dated edition for personal use; redistribution prohibited.
Next dated catalyst
Third quarter, reported November 9, 2026: net loss of $110.4 million, or $1.11 per share, on research and development of $95.6 million and other income of $11.5 million; cash, equivalents and marketable securities were $1,153.5 million at September 30, 2026, with funding into 2029. Release, November 9, 2026
December 2026 · X-NOVA2 topline results in major depressive disorder
Xenon completed enrollment in the Phase 3 X-NOVA2 study in major depressive disorder with about 360 patients and now expects topline data in December 2026, earlier than the first quarter of 2027 previously guided. New enrollment in the MDD and bipolar-depression studies remains voluntarily paused after an analysis of neuropsychiatric adverse events; participants already enrolled stay active, and the epilepsy studies continue. Q3 2026 release, November 9, 2026
Also scheduled: new azetukalner and epilepsy data at the American Epilepsy Society 2026 Annual Meeting in Denver, December 4–8, 2026, and investor conferences on November 11 (Stifel, New York), November 18 (Jefferies, London) and December 1 (Evercore, Coral Gables), after the fireside chat scheduled at the Guggenheim conference in Boston on November 10. Planned: initiation of the Phase 3b/4 X-FIRST study in the first quarter of 2027. Company schedule and pipeline
XENE stock at a glance
Regular-session closing price
41.39
USD per share · 2026-11-10 · November 10, 2026 regular-session close; previous close $40.45.
Reference equity value
4,068,005,140.26
USD · 2026-11-10 · Calculated as $41.39 multiplied by 98,284,734 common shares reported outstanding on November 5, 2026. The share count and price have different reference dates.
Primary sourceCash, equivalents and marketable securities
1,153.5
USD million · 2026-09-30 · $950.8 million current and $202.7 million non-current; funding guided into 2029.
Primary sourceNet loss
110.4
USD million · Q3 2026 · $1.11 per share, against $90.9 million and $1.15 a year earlier.
Primary sourceOperating cash used
274.6
USD million · Nine months ended September 30, 2026, against $197.6 million a year earlier.
Primary sourceCommon shares and pre-funded warrants
98,284,734 common shares reported on November 5; 1,507,885 pre-funded warrants outstanding at September 30.
securities · 2026-11-05
Primary sourceX-TOLE2 primary endpoint
53.2% median seizure reduction at 25 mg versus 10.4% with placebo over twelve weeks.
X-TOLE2 topline announcement, March 9, 2026
Primary sourceResearch and development expense
95.6
USD million · Quarter ended September 30, 2026, against $77.1 million a year earlier.
Primary sourceWhere Xenon Pharmaceuticals stands now
The focal-seizure application brings randomized X-TOLE and X-TOLE2 evidence into the regulatory review that follows submission. In X-TOLE2, median monthly seizure reduction over twelve weeks was 53.2% with 25 mg and 34.5% with 15 mg, compared with 10.4% on placebo. A future regulatory decision and approved instructions would define the scope of the commercial opportunity.
Xenon is preparing for that possibility while reassessing psychiatric dosing and developing earlier pain candidates. Cash, equivalents and marketable securities were $1,153.5 million at September 30, 2026, after $274.6 million of cash used in operations over the first nine months. The third quarter produced a $110.4 million net loss, or $1.11 per share, and management guided to funding operations into 2029 under its operating plan. New enrollment in the depression studies stays paused, but X-NOVA2 enrollment is complete at about 360 patients. Third-quarter 2026 release.
Azetukalner accounts for much of the nearer clinical and commercial opportunity. The psychiatric enrollment pause highlights the need to understand tolerability by population and regimen, while the epilepsy application retains its own regulatory assessment. With X-NOVA2 enrollment closed at about 360 patients, the topline readout now guided to December 2026 should answer the tolerability question within weeks rather than quarters. A successful approval would still require reliable supply, patient access and sustained prescribing to justify launch expenditure.
The constructive case
A satisfactory focal-seizure regulatory outcome and a practical oral product profile support a durable specialist launch. The balance sheet permits disciplined development, while pain programs add longer-term options.
The cautious case
Psychiatric tolerability and concentration around one molecule can narrow future opportunities. A December 2026 X-NOVA2 readout that fails to separate from placebo, or that carries an adverse-event profile the company cannot manage, would remove the psychiatry optionality while spending continues. Labeling, competition, patient access and sustained expenditure can absorb resources despite a strong reported balance.
Read also: Praxis $PRAX $RAPP $STOK $XENE: Beyond Seizure Counts →
Latest Xenon Pharmaceuticals news
Nov 9, 2026
Xenon reports Q3 2026 financial results and provides business update
Xenon reported a net loss of $110.4 million for the quarter ended September 30, 2026, compared to $90.9 million for the same period in 2025. Cash, cash equivalents and marketable securities were $1,153.5 million, with cash expected to fund operations into 2029. The company submitted its New Drug Application for azetukalner in focal seizures to the FDA in September 2026, and the topline data readout from the Phase 3 X-NOVA2 study in MDD is now expected in December 2026.
Nov 3, 2026
Xenon to present at upcoming investor conferences
Xenon Pharmaceuticals will present at four investor conferences in the fourth quarter of 2026, each as a fireside chat. The events are the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on November 10, 2026; the Stifel 2026 Healthcare Conference in New York, NY on November 11, 2026; the 2026 Jefferies Global Healthcare Conference in London, UK on November 18, 2026; and the 9th Annual Evercore Healthcare Conference in Coral Gables, FL on December 1, 2026. Dates and times are subject to change, and webcasts will be posted for replay on the Investors section of Xenon's website.
Nov 2, 2026
Xenon to Report Q3 2026 Financial Results on November 9, 2026
Xenon Pharmaceuticals will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay afterward. The dates and times are subject to change.
Oct 30, 2026
Employee inducement equity awards disclosed
Xenon disclosed inducement equity grants for newly hired employees under Nasdaq Listing Rule 5635(c)(4).
Oct 29, 2026
Pain programs prepare for Phase 2 proof of concept
Phase 1 and preclinical findings for XEN1701 and XEN1120 support plans to start acute-pain proof-of-concept studies in the first half of 2027.
Oct 2, 2026
New-employee inducement grants
Eight new non-officer employees received 17,850 options and 10,500 restricted share units, effective October 1, 2026.
XENE stock catalysts
- December 2026 · X-NOVA2 topline results in major depressive disorderCompany guidance, November 9, 2026 · enrollment complete at about 360 patients
Earlier than the first quarter of 2027 previously guided. Q3 2026 release
- November 9, 2026 · Third-quarter 2026 results reportedReported · after the U.S. close
Net loss of $110.4 million, or $1.11 per share; cash and securities of $1,153.5 million at September 30. Form 8-K, Exhibit 99.1
- November 10, 2026 · Fireside chat, Guggenheim 3rd Annual Healthcare Innovation Conference, BostonCompany-announced · scheduled date passed
- November 11, 2026 · Fireside chat, Stifel 2026 Healthcare Conference, New YorkCompany-announced · date subject to change
- November 18, 2026 · Fireside chat, Jefferies Global Healthcare Conference, LondonCompany-announced · date subject to change
- December 1, 2026 · Fireside chat, 9th Annual Evercore Healthcare Conference, Coral GablesCompany-announced · date subject to change
- December 4–8, 2026 · American Epilepsy Society 2026 Annual Meeting, DenverCompany-announced · new azetukalner and epilepsy data expected
- 2026 · X-TOLE3 enrollment outside Japan expected to completeCompany guidance, November 9, 2026
- 2027-Q1 · Initiation of the Phase 3b/4 X-FIRST study in focal seizuresCompany target, November 9, 2026
- 2027-H1 · Initiation of XEN1701 and XEN1120 acute-pain phase 2 proof-of-concept studiesCompany target announced October 29, 2026
- 2027-04 · X-ACKT primary completionClinicalTrials.gov estimate; primary completion differs from a results announcement
- 2028-01 · X-TOLE3 primary completionClinicalTrials.gov estimate; primary completion differs from a results announcement
- Unscheduled · FDA filing review and any assigned application-review targetNDA submitted September 2026; subsequent regulatory milestone
- Unscheduled · Psychiatry dose-regimen reassessment and enrollment plansNew enrollment paused since September 2026
Azetukalner programs occupy different stages
| Program | Current position | Next information |
|---|---|---|
| Focal seizures | NDA submitted September 17, 2026, supported by randomized X-TOLE and X-TOLE2 studies; awaiting FDA filing review | Filing acceptance, any assigned review target and a future decision |
| Major depressive disorder | X-NOVA2 enrollment complete at about 360 participants; new enrollment in the psychiatry studies paused since September 2026 | Topline results guided to December 2026 |
| Broader epilepsy | X-TOLE3 and X-ACKT continue development; X-FIRST planned as a Phase 3b/4 first-add-on study | X-TOLE3 enrollment outside Japan expected to complete in 2026; X-FIRST planned for the first quarter of 2027 |
Financial resources and ownership have different reference dates
| Measure | Reported value | Reference |
|---|---|---|
| Cash, equivalents and marketable securities | $1,153.5 million | September 30, 2026 |
| Operating cash used | $274.617 million | Nine months ended September 30, 2026 |
| Common shares | 98,284,734 | November 5, 2026 |
| Pre-funded warrants | 1,507,885 | September 30, 2026 |
Merlintrader Health Score · $XENE
3.30out of 5
Reassessed November 10, 2026, on the third-quarter 2026 results and the November 10 close; pillar scores unchanged from the November 9 assessment: 0.3 × 4 + 0.3 × 3 + 0.2 × 3 + 0.1 × 3 + 0.1 × 3 = 3.3. An editorial assessment of financial and operating resilience over twelve to eighteen months; no price target or recommendation is implied.
Red flags
- The focal-seizure regulatory decision and eventual prescribing instructions remain ahead.
- New psychiatry enrollment is paused while Xenon evaluates possible dosing changes; the December 2026 X-NOVA2 readout is the next test of that program.
- Several opportunities depend on the same lead molecule, concentrating clinical and commercial exposure.
- A first launch could increase spending before product revenue becomes meaningful; operating cash use reached $274.6 million in the first nine months of 2026.
- Common shares rose 22.8 per cent from December 31, 2025 to September 30, 2026, and pre-funded warrants, employee awards and future issuance can dilute existing owners further.
- Early pain studies have established exposure and tolerability information; patient analgesic efficacy remains to be tested.
- Registry completion estimates are planning dates and can differ from company readout guidance.
XENE Stock FAQ: Xenon Pharmaceuticals Questions Answered
What is the next XENE stock catalyst?
Xenon now guides X-NOVA2 topline results in major depressive disorder to December 2026, after completing enrollment with about 360 patients; the earlier guidance was the first quarter of 2027 (Q3 2026 release, November 9, 2026). The company also expects new azetukalner and epilepsy data at the American Epilepsy Society annual meeting in Denver on December 4–8, 2026, and plans to start the Phase 3b/4 X-FIRST study in the first quarter of 2027. The focal-seizure application submitted in September remains with the FDA, with filing acceptance and any review goal date still unannounced. Q3 2026 release. Company schedule and pipeline.
Is Xenon’s azetukalner FDA approved for focal seizures?
No: azetukalner is not approved for any indication as of November 10, 2026. Xenon submitted the focal-seizure New Drug Application in September 2026 and restated the submission in its third-quarter results release; a submission does not grant marketing approval. Filing review, substantive assessment and a future decision remain ahead, and X-TOLE3 and X-ACKT are continuing epilepsy studies. Q3 2026 development update. NDA submission and epilepsy program.
How much cash does Xenon Pharmaceuticals have, and how long will it last?
Xenon held $1,153.5 million of cash, equivalents and marketable securities at September 30, 2026 and guided to funding operations into 2029 under its operating plan (Q3 2026 results, November 9, 2026). Of that total, $950.8 million was classified as current and $202.7 million as non-current, against $586.0 million at December 31, 2025. Operating cash use was $274.6 million in the first nine months of 2026. Q3 2026 release. Form 10-Q, cash-flow statement.
Could XENE stock be diluted by new shares or warrants?
Xenon reported 98,284,734 common shares outstanding at November 5, 2026 and 1,507,885 pre-funded warrants at September 30, 2026; the at-the-market program permits up to $400 million of gross common-share sales, and employee awards add further potential dilution (Form 10-Q, November 9, 2026). Common shares rose from 80,010,790 at December 31, 2025, after the March offering and after $130.0 million of at-the-market sales completed by February 26, 2026. Share capital, warrants and at-the-market program.
When does Xenon Pharmaceuticals report earnings?
Xenon reported third-quarter 2026 results after the U.S. market close on November 9, 2026: a net loss of $110.4 million, or $1.11 per share, with $1,153.5 million of cash and securities (Q3 2026 release, November 9, 2026). The date of the fourth-quarter and full-year 2026 report has not been announced. Third-quarter 2026 results.
What does Xenon Pharmaceuticals do?
As of November 10, 2026, Xenon is a neuroscience-focused biotechnology company developing treatments for epilepsy, psychiatric disorders and pain. Its lead program, azetukalner, opens KV7 potassium channels and is in late-stage development, with a focal-seizure New Drug Application awaiting FDA filing review. Potassium- and sodium-channel programs for pain are in Phase 1, with Phase 2 proof-of-concept studies planned for the first half of 2027. Company and pipeline overview. Lead-program regulatory stage.
Why did Xenon pause enrollment in depression studies?
Xenon paused new enrollment in its Phase 3 psychiatry studies in September 2026 after an analysis of neuropsychiatric adverse events; participants already enrolled remained active and the epilepsy studies were unaffected. On November 9, 2026 the company said X-NOVA2 enrollment in major depressive disorder is complete with about 360 patients and topline results are now expected in December 2026, while the pause on new enrollment continues and dosing is being reassessed. Q3 2026 update on the psychiatry program. September 2026 announcement.
When will Xenon start the XEN1701 and XEN1120 pain trials?
Xenon targets initiation of Phase 2 proof-of-concept studies of XEN1701 and XEN1120 in acute pain during the first half of 2027, a plan repeated in its November 9, 2026 results release. Phase 1 findings concern safety, tolerability and drug exposure in healthy participants. Supportive animal-model findings are preclinical evidence, rather than proof of pain relief in patients. Q3 2026 pain-program update. October 2026 findings.
Primary sources and market references
- November 9, 2026 — Third-quarter 2026 results and business update (Form 8-K, Exhibit 99.1)
- November 9, 2026 — Quarterly report on Form 10-Q for the quarter ended September 30, 2026
- November 2, 2026 — Q3 2026 results and business update on November 9
- Xenon investor relations (company announcements)
- filed share-count reference
- September regulatory and clinical announcement
- Company history and leadership
- ILAE definition
- drug-resistant epilepsy resources
- European Epilepsy Congress program announcement
- FDA safety communication on the earlier medicine
- Original X-TOLE publication
- March topline release filed with the SEC
- X-TOLE2 scientific poster
- Long-term X-TOLE poster
- FDA development and review framework
- X-TOLE3 registry
- X-ACKT registry
- X-TOLE4 registry
- X-NOVA2 registry
- bipolar-depression registry
- October pain-program announcement
- Second-quarter results
- March offering close
- FMR beneficial-ownership filing
- Proxy ownership table
- FDA cenobamate prescribing information
- October 2 employee grants
- October 30 announcement
Disclaimer. Published by Merlintrader for educational and informational purposes only. This content does not constitute investment advice or a recommendation to buy, sell or hold securities. Verify figures against the dated primary disclosures. Investors can lose part or all of their capital.
Neuroscience drug development involves clinical, safety, regulatory, manufacturing, access and competitive risks. Trials may fail or require additional work, product approval and successful commercialization are uncertain, and continued development can consume substantial cash. Equity financing and employee awards can dilute shareholders, while concentration around a lead molecule can connect risks across several indications.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information: disclaimer and terms of use and privacy.



